Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach

Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach

Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, i...

Full description

Bibliographic Details
Main Authors: Alessandro Isidori, Federica Loscocco, Marilena Ciciarello, Giulia Corradi, Mariangela Lecciso, Darina Ocadlikova, Sarah Parisi, Valentina Salvestrini, Sergio Amadori, Giuseppe Visani, Antonio Curti
Format: Article
Language:English
Published: MDPI AG 2018-06-01
Series:Cancers
Subjects:
acute myeloid leukemia
tumor immunity
immunotherapy
immunosenescence
new drugs
cell therapy
Online Access:http://www.mdpi.com/2072-6694/10/7/211

Similar Items

Similar Items